Abstract
Background: Poor ovarian response (POR) represents a major challenge in assisted reproductive technology, frequently resulting in reduced oocyte yield and impaired reproductive outcomes. Dual trigger protocols combining gonadotropin-releasing hormone agonist (GnRH-a) with human chorionic gonadotropin (hCG) have been proposed to improve final oocyte maturation and pregnancy outcomes in women with POR classified according to the Bologna and POSEIDON criteria. However, available evidence remains inconsistent. Objective: To evaluate the effectiveness of dual trigger protocol compared with hCG trigger alone in women with poor ovarian response undergoing assisted reproductive treatment. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO. MEDLINE, Embase, Cochrane CENTRAL, and Scopus were searched from 2000 to January 2026. Randomized and observational studies comparing dual triggers with hCG triggers alone in women diagnosed with poor ovarian response according to the Bologna and/or POSEIDON criteria were eligible. Outcomes included retrieved and mature (MII) oocytes, clinical pregnancy, miscarriage, and live birth. Random effects models were used for the primary analyses. Exploratory univariable meta-regression evaluated age, AFC, AMH, study design, and POR classification as potential moderators. Certainty of evidence was assessed using GRADE. Results: Twenty studies were included, of which 16 contributed data to at least one quantitative synthesis. Dual trigger was associated with a significantly higher number of mature (MII) oocytes in Bologna-defined women (MD 0.62, 95% CI 0.29–0.96; I2 = 83%) and in the overall population combining Bologna- and POSEIDON-defined women (MD 0.50, 95% CI 0.20–0.79; I2 = 91%), whereas no significant difference was observed in POSEIDON-defined women (MD 0.37, 95% CI −0.14 to 0.89; I2 = 93%). In the nested POSEIDON groups 3/4 subgroup, random effects analyses showed no significant differences in MII oocyte yield (MD 0.11, 95% CI −0.59 to 0.81), clinical pregnancy (OR 1.15, 95% CI 0.45–2.97), or live birth (OR 1.18, 95% CI 0.53–2.64). Lower miscarriage odds were observed in this subgroup (OR 0.43, 95% CI 0.30–0.63), based on two studies and heavily influenced by one large study. The number of retrieved oocytes was significantly higher with dual trigger protocol in Bologna-defined women (MD 0.71, 95% CI 0.33–1.09; I2 = 86%) and in the overall population (MD 0.62, 95% CI 0.27–0.97; I2 = 93%), but not in POSEIDON-defined women (MD 0.53, 95% CI −0.00 to 1.06; I2 = 91%); a separate estimate for POSEIDON groups 3/4 was unavailable. Clinical pregnancy was higher with dual trigger in Bologna-defined women (OR 1.29, 95% CI 1.03–1.61; I2 = 14%), whereas no significant difference was observed in POSEIDON-defined women (OR 1.10, 95% CI 0.78–1.56; I2 = 68%). No significant differences were observed for miscarriage or live birth in the overall analyses. Sensitivity analyses excluding studies at high or serious overall risk of bias attenuated the associations for oocyte-related outcomes in the combined population, although they persisted in Bologna-defined women, and did not demonstrate significant differences in reproductive outcomes. Exploratory meta-regression identified no significant effect modification by age, AFC, AMH, study design, or POR classification (all p > 0.05). Conclusions: Dual trigger may modestly improve oocyte yield and maturation in women with poor ovarian response, although these effects appear to vary according to POR classification and were attenuated in sensitivity analyses excluding studies at high or serious risk of bias. Although higher clinical pregnancy rates were observed in Bologna-defined women, no significant benefit was demonstrated for miscarriage or live birth. Thus, the available evidence suggests a potential effect of dual trigger on intermediate ovarian outcomes but does not establish that these improvements translate into better reproductive outcomes. Further adequately powered randomized controlled trials are needed to determine whether specific subgroups of poor ovarian responders may derive a clinically meaningful benefit.

This publication has 44 references indexed in Scilit: